TP53 and cancer: Overexpression of MIF was found to stimulate proliferation of cancer cells via activation of the ERK/MAPK pathway and inhibition of the p53 pathway.[49, 50] Therefore, a number of MIF targeting modalities have been reported as potential treatments, including mAbs,[51] peptides,[52] small‐molecule inhibitors[24, 25] etc. These modalities have been successfully applied in animal models for MIF‐related diseases.[52] However, there is no clinically approved MIF‐directed drug available yet.